A single administration of gemtuzumab ozogamicin for molecular relapse of acute promyelocytic leukemia [1]

Hematology Journal

Volumn 5, Issue 3, 2004, Pages 279-280

  Schwarz, Jiří ^a   Marková, Jana ^a   Peková, Soňa ^a   Trnková, Zuzana ^a   Šponerová, Dana ^a   Cetkovský, Petr ^a  

^a INSTITUTE OF HEMATOLOGY AND BLOOD TRANSFUSION   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

ARSENIC TRIOXIDE; CYTARABINE; GEMTUZUMAB OZOGAMICIN; IDARUBICIN; MITOXANTRONE; RETINOIC ACID;

ADULT; ARTIFICIAL VENTILATION; CANCER RECURRENCE; CANCER REGRESSION; CASE REPORT; DRUG DOSE REGIMEN; DRUG SAFETY; FEVER; HEMOPHAGOCYTIC SYNDROME; HUMAN; JAUNDICE; LETTER; LIVER DISEASE; LIVER TOXICITY; MALE; MENINGITIS; PANCYTOPENIA; PROMYELOCYTIC LEUKEMIA; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SINGLE DRUG DOSE; VIRUS PNEUMONIA;

ADULT; AMINOGLYCOSIDES; ANTIBODIES, MONOCLONAL; HUMANS; IMMUNOTOXINS; LEUKEMIA, PROMYELOCYTIC, ACUTE; LEUKOCYTE COUNT; MALE; NEOPLASM, RESIDUAL; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TREATMENT OUTCOME; TRETINOIN;

EID: 3142777193     PISSN: 14664860     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.thj.6200367     Document Type: Letter

References (10)

1. Mandelli F, Diverio D, Avvisati G, Luciano A, Barbui T, Bernasconi C et al. Molecular remission in PML/RARα-positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy. Blood 1997; 90: 1014-1021.
2. Lo Coco F, Diverio D, Falini B, Biondi A, Nervi C, Pelieci PG. Genetic diagnosis and molecular monitoring in the management of acute promyelocytic leukemia. Blood 1999; 94: 12-22.
3. Tallman MS, Nabhan C, Feusner JH, Rowe JM. Acute promyelocytic leukemia: evolving therapeutic strategies. Blood 2002; 99: 759-767.
4. Diverio D, Rossi V, Avvisati G, De Santis S, Pistilli A, Pane F et al. Early detection of relapse by prospective reverse transcriptase-polymerase chain reaction analysis of the PML/RARα fusion gene in patients with acute promyelocytic leukemia enrolled in the GIMEMA-AIEOP multicenter 'AIDA' trial. Blood 1998; 92: 784-789.
5. Lo Coco F, Diverio D, Avvisati G, Petti MC, Meloni G, Pogliani EM et al. Therapy of molecular relapse in acute promyelocytic leukemia. Blood 1999; 94: 2225-2229.
6. Tamura S, Takemoto Y, Takami S, Kinoshita M, Kumano Y, Aono H et al. Efficacy of all-trans retinoic acid for molecular relapse of acute promyelocytic leukemia during remission. Oncol Rep 1999; 6: 683-685.
7. Visani G, Buonamici S, Malagola M, Isidori A, Piccaluga PP, Martinelli G et al. Pulsed ATRA as single therapy restores long-term remission in PML-RARα-positive acute promyelocytic leukemia patients: real time quantification of minimal residual disease. A pilot study. Leukemia 2001; 15: 1696-1700.
8. Petti MC, Pinazzi MB, Diverio D, Romano A, Petrucci MT, De Santis S et al. Prolonged molecular remission in advanced acute promyelocytic leukaemia after treatment with gemtuzumab ozogamicin (Mylotarg CMA-676). Br J Haematol 2001; 115: 63-65.
9. Biondi A, Rambaldi A, Pandolfi PP, Rossi V, Giudici G, Alcalay M et al. Molecular monitoring of the myl/retinoic acid receptor-α fusion gene in acute promyelocytic leukemia by polymerase chain reaction. Blood 1992; 80: 492-497.
10. Cassinat B, Zassadowski F, Balitrand N, Barbey C, Rain JD, Fenaux P et al. Quantitation of minimal residual disease in acute promyelocytic leukemia patients with t(15;17) translocation using real-time RT-PCR. Leukemia 2000; 14: 324-328.